Postprandial Hypoglycemia Clinical Trial
Official title:
Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass
The aim of this study is investigating the effect of a novel glucagon analogue administration in gastric bypass operated individuals, who are reactive hypoglycemic.
The Roux-En-Y gastric bypass (RYGB) has major health-promoting effects - reversing
type-2-diabetes, improving dyslipidemia and inducing robust weight loss. However, several
RYGB-individuals, post surgery, suffers from dumping syndrome and postprandial
hyperinsulinemic hypoglycemia (PHH) due to the anatomical rearrangement of the
gastro-intestinal system. Dasiglugaon (also known as (ZP4207) has shown great
pharmacokinetic- and dynamic effects, compared to other glucagon analogues on the market,
when administrated to hypoglycemic type-1-diabetics.
Therefore we aim to examine the effects of two different doses of dasiglucagon on the
postprandial nadir plasma glucose concentration in RYGB-operated individuals suffering from
PHH by use of a mixed meal test (MMT).
The study is designed as a double-blinded, randomised, 3-period, 3-treatment, crossover study
comprising 3 separate treatment days in which participants will undergo an MMT along with one
of the following double-blinded interventions:
1. Subcutaneous (sc) placebo (saline) injection
2. Sc injection with 80 μg dasiglucagon
3. Sc injection with 200 μg dasiglucagon
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03200782 -
Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study
|
N/A | |
Recruiting |
NCT05036317 -
Empagliflozin for the Treatment of Postprandial Hypoglycemia
|
Phase 3 | |
Active, not recruiting |
NCT05174507 -
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
|
Phase 2 | |
Completed |
NCT04330196 -
Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance.
|
N/A | |
Recruiting |
NCT04720859 -
Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)
|
N/A | |
Completed |
NCT05676385 -
Glucose Response to a Formula for Patients at Risk of Hypoglycaemia
|
N/A | |
Completed |
NCT04836273 -
Treatment of Post-bariatric Hypoglycaemia
|
Phase 2 | |
Completed |
NCT05513404 -
The Scottish Fruit Study
|
N/A | |
Completed |
NCT01162499 -
Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia
|
N/A | |
Recruiting |
NCT05401578 -
Canakinumab for the Treatment of Postprandial Hypoglycemia
|
Phase 3 |